Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
91 hedge funds and large institutions have $303M invested in Stemline Therapeutics, Inc. in 2018 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 14 closing their positions.
65% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 20
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
11% more funds holding
Funds holding: 82 → 91 (+9)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $310M → $303M (-$7.09M)
90% less call options, than puts
Call options by funds: $330K | Put options by funds: $3.44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$27.5M |
| 2 |
BlackRock
New York
|
+$5.02M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$4.29M |
| 4 |
Two Sigma Investments
New York
|
+$4.28M |
| 5 |
LSC
Lyon Street Capital
Sausalito,
California
|
+$4.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$20.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$11.3M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$8.02M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$4.34M |
| 5 |
Axa
Paris,
France
|
-$2.01M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SI
101
Sofinnova Investments
Menlo Park,
California
| – | -$193K | -12,640 | Closed |
|
|
RA
102
Royce & Associates
New York
| – | -$104K | -6,800 | Closed |
|
|
PAM
103
Panagora Asset Management
Boston,
Massachusetts
| – | -$25K | -1,640 | Closed |
|
104
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$23K | -1,500 | Closed |
|
|
MAM
105
Meeder Asset Management
Dublin,
Ohio
| – | -$1K | -90 | Closed |
|
STML Hedge Fund Activity: Q2 2018 in Review
91 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q2 2018, worth a combined $303M — down 2.3% from $310M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new STML positions and 14 closed out — a net gain of 9 holders — while 33 added to existing stakes and 20 trimmed.
The largest buyer was Polar Capital, adding an estimated $27.5M. The largest seller was Fidelity Investments, cutting an estimated $20.7M.
- 91 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q2 2018, up from 82 in Q1 2018.
- Funds reported $303M of Stemline Therapeutics, Inc. stock for Q2 2018, down 2.3% quarter-over-quarter.
- 23 funds opened new Stemline Therapeutics, Inc. positions in Q2 2018 and 14 closed out, a net change of +9 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q2 2018 was Polar Capital, an estimated $27.5M added.
- The largest Stemline Therapeutics, Inc. seller in Q2 2018 was Fidelity Investments, an estimated $20.7M sold.
Based on aggregated 13F filings for Q2 2018.